Wouter P Te Rijdt1,2,3, Judith N Ten Sande2,4, Thomas M Gorter1, Paul A van der Zwaag3, Ingrid A van Rijsingen4, S Matthijs Boekholdt4, J Peter van Tintelen5, Paul L van Haelst6,7, R Nils Planken8, Rudolf A de Boer1, Albert J H Suurmeijer9, Dirk J van Veldhuisen1, Arthur A M Wilde4, Tineke P Willems10, Pascal F H M van Dessel4,11, Maarten P van den Berg1. 1. Department of Clinical and Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 2. Netherlands Heart Institute (Nl-HI), Utrecht, the Netherlands. 3. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 4. Department of Clinical and Experimental Cardiology, Heart Center, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands. 5. Department of Clinical Genetics, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands. 6. Department of Cardiology, Antonius Hospital, Sneek, the Netherlands. 7. Roche Diagnostics, Basel, Switzerland. 8. Department of Radiology, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands. 9. Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 10. Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 11. Department of Cardiology, Medisch Spectrum Twente, Enschede, the Netherlands.
Abstract
Aims: The p.Arg14del founder mutation in the gene encoding phospholamban (PLN) is associated with an increased risk of malignant ventricular arrhythmia (VA) and heart failure. It has been shown to lead to calcium overload, cardiomyocyte damage, and eventually to myocardial fibrosis. This study sought to investigate ventricular function, the extent and localization of myocardial fibrosis and the associations with ECG features and VA in PLN p.Arg14del mutation carriers. Methods and results: Cardiovascular magnetic resonance (CMR) data of 150 mutation carriers were analysed retrospectively. Left ventricular (LV) and right ventricular (RV) volumes, mass, and ejection fraction were measured. The extent of late gadolinium enhancement (LGE) was expressed as a percentage of myocardial mass. All standard ECG parameters were measured. Occurrence of VA was analysed on ambulatory 24-h and/or exercise electrocardiography, if available. Mean age was 40 ± 15 years, 42% males, and 7% were index patients while 93% were pre-symptomatic carriers identified after family cascade screening. Mean LV ejection fraction (LVEF) and RV ejection fraction were 58 ± 9% and 55 ± 9%, respectively. LV-LGE was present in 91% of mutation carriers with reduced LVEF (<45%) and in 30% of carriers with preserved LVEF. In carriers with positive LV-LGE, its median extent was 5.9% (interquartile range 3.2-12.7). LGE was mainly observed in the inferolateral wall. Carriers with inverted T-waves in the lateral ECG leads more often had LV-LGE (P < 0.01) than carriers without. Finally, the presence of LV-LGE, but not attenuated R-waves and inverted lateral T-waves, was independently associated with VA. Conclusion: LV myocardial fibrosis is present in many PLN p.Arg14del mutation carriers, and who still have a preserved LVEF. It is seen predominantly in the LV inferolateral wall and corresponds with electrocardiographic repolarization abnormalities. Although preliminary, myocardial fibrosis was found to be independently associated with VA. Our findings support the use of CMR with LGE early in the diagnostic work-up.
Aims: The p.Arg14del founder mutation in the gene encoding phospholamban (PLN) is associated with an increased risk of malignant ventricular arrhythmia (VA) and heart failure. It has been shown to lead to calcium overload, cardiomyocyte damage, and eventually to myocardial fibrosis. This study sought to investigate ventricular function, the extent and localization of myocardial fibrosis and the associations with ECG features and VA in PLN p.Arg14del mutation carriers. Methods and results: Cardiovascular magnetic resonance (CMR) data of 150 mutation carriers were analysed retrospectively. Left ventricular (LV) and right ventricular (RV) volumes, mass, and ejection fraction were measured. The extent of late gadolinium enhancement (LGE) was expressed as a percentage of myocardial mass. All standard ECG parameters were measured. Occurrence of VA was analysed on ambulatory 24-h and/or exercise electrocardiography, if available. Mean age was 40 ± 15 years, 42% males, and 7% were index patients while 93% were pre-symptomatic carriers identified after family cascade screening. Mean LV ejection fraction (LVEF) and RV ejection fraction were 58 ± 9% and 55 ± 9%, respectively. LV-LGE was present in 91% of mutation carriers with reduced LVEF (<45%) and in 30% of carriers with preserved LVEF. In carriers with positive LV-LGE, its median extent was 5.9% (interquartile range 3.2-12.7). LGE was mainly observed in the inferolateral wall. Carriers with inverted T-waves in the lateral ECG leads more often had LV-LGE (P < 0.01) than carriers without. Finally, the presence of LV-LGE, but not attenuated R-waves and inverted lateral T-waves, was independently associated with VA. Conclusion: LV myocardial fibrosis is present in many PLN p.Arg14del mutation carriers, and who still have a preserved LVEF. It is seen predominantly in the LV inferolateral wall and corresponds with electrocardiographic repolarization abnormalities. Although preliminary, myocardial fibrosis was found to be independently associated with VA. Our findings support the use of CMR with LGE early in the diagnostic work-up.
Authors: J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson Journal: Circ Res Date: 2022-05-26 Impact factor: 23.213
Authors: Dirk J van Veldhuisen; Gijs van Woerden; Thomas M Gorter; Vanessa P M van Empel; Olivier C Manintveld; Robert G Tieleman; Alexander H Maass; Kevin Vernooy; B Daan Westenbrink; Isabelle C van Gelder; Michiel Rienstra Journal: Eur J Heart Fail Date: 2020-08-21 Impact factor: 15.534
Authors: Stephanie M van der Voorn; Mimount Bourfiss; Anneline S J M Te Riele; Karim Taha; Marc A Vos; Remco de Brouwer; Tom E Verstraelen; Rudolf A de Boer; Carol Ann Remme; Toon A B van Veen Journal: Front Cardiovasc Med Date: 2022-01-13
Authors: Viraj Patel; Babken Asatryan; Bhurint Siripanthong; Patricia B Munroe; Anjali Tiku-Owens; Luis R Lopes; Mohammed Y Khanji; Alexandros Protonotarios; Pasquale Santangeli; Daniele Muser; Francis E Marchlinski; Peter A Brady; C Anwar A Chahal Journal: Int J Mol Sci Date: 2020-09-10 Impact factor: 5.923
Authors: W P Te Rijdt; E T Hoorntje; R de Brouwer; A Oomen; A Amin; J F van der Heijden; J C Karper; B D Westenbrink; H H W Silljé; A S J M Te Riele; A C P Wiesfeld; I C van Gelder; T P Willems; P A van der Zwaag; J P van Tintelen; J H Hillege; H L Tan; D J van Veldhuisen; F W Asselbergs; R A de Boer; A A M Wilde; M P van den Berg Journal: Neth Heart J Date: 2021-06-18 Impact factor: 2.380
Authors: Gijs van Woerden; Dirk J van Veldhuisen; Thomas M Gorter; Tineke P Willems; Vanessa P M van Empel; Aniek Peters; Gabija Pundziute; Jeroen W Op den Akker; Michiel Rienstra; B Daan Westenbrink Journal: Heart Vessels Date: 2021-07-22 Impact factor: 2.037